ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
“That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product,” the analyst adds. Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults. In the second quarter of 2024, net sales of Qelbree increased 92% year over year to $59.4 million, and total IQVIA prescriptions were 184,342, up 26%. Piper writes that the management's focus on optimizing Qelbree's net economics, such as reducing copay assistance, suggests that future volume growth may be more modest. While initial estimates projected peak sales nearing $500 million, Piper writes that $400 million is a more realistic target. The Piper analyst writes that Qelbree is growing and highlights that YTD prescriptions increased 91% in 2023 compared to 2022. Piper has downgraded Supernus Pharmaceuticals to Neutral from Overweight, with a price target of $36, down from $41 Quarter-to-date prescriptions have grown by about 1
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceGlobeNewswire
- Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 11/4/24 - Beat
SUPN
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- 11/12/24 - Form 4
- SUPN's page on the SEC website